Abstract Prostate cancer is a major cause of cancer death among elderly men in America, Europe, and Japan. However, the molecular mechanism of carcinogenesis is not yet well characterized. Frequent loss of heterozygosity (LOH) on chromosome 10q was reported in prostate cancer, and a candidate tumor suppressor gene, PTEN, was isolated on chromosome band 10q23.3. To investigate the genetic alterations of PTEN, we examined 45 primary prostate cancer specimens. LOH at the PTEN locus was observed in two (11.1%) of 18 tumors. However, no mutations were observed in any of the primary prostate cancers. These data suggest that mutation of the PTEN gene does not play a major role in prostate carcinogenesis of Japanese patients.
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Introduction
Prostate cancer is the second leading cause of cancer deaths in males in the United States and the eighth in Japan. Despite the high incidence and mortality, molecular mechanisms underlying tumorigenesis and progression of prostate cancer are still open questions. Cytogenetic and loss of heterozygosity (LOH) studies have pointed out that a number of chromosomal regions, including 10q, are frequently lost in prostate cancer (Carter et al. 1990) . One candidate gene, MXI1, which encodes a negative regulator of the Myc oncoprotein, was mapped to chromosome bands 10q24-q25. However, the incidence of mutation of MXI1 in prostate cancer was not high (Eagle et al. 1995) . More recently, PTEN, a candidate tumor suppressor gene, was isolated on chromosome 10q23.3 Steck et al. 1997; Li and Sun 1997) , a region of frequent allelic loss in prostate cancer. Mutational analysis of this gene revealed that it was mutated in prostate cancers Steck et al. 1997) . However, the incidence of mutation was much higher in endometrial cancers (Kong et al. 1997; Tashiro et al. 1997; Risinger et al. 1997 ) and it is not clear whether or not mutations of PTEN are deeply involved in prostate carcinogenesis. Hence, we analyzed this gene in primary prostate cancer.
Materials and methods
A total of 45 paired specimens of primary prostate cancers and corresponding normal tissues from Japanese patients at Tohoku University Hospital (Sendai, Japan) and Yokohama City University Hospital (Yokohama, Japan) were analyzed. Twenty-seven specimens were snap-frozen in liquid nitrogen immediately after surgical resection and stored at Ϫ80°C until DNA extraction. Eighteen samples, fixed in formalin and embedded in paraffin, were retrieved from the surgical pathology file of the Division of Pathology, Tohoku University Hospital. Tumors were classified according to the Whitmore-Jewette system in clinical stages (Prout 1973) . In terms of histologic subtypes or stages, there was no bias between samples of frozen tissue and those from paraffin blocks. Details of patients are summarized in Table 1 .
Results
First, we analyzed LOHs in 19 primary prostate cancers in which relatively large amounts of DNA were available. LOHs were studied utilizing the 5-bp insertion/deletion in Case 20. There were no discrepancies between microsatellite and FISH analyses.
Next we analyzed mutations of PTEN in DNA from 27 primary prostate cancers in which the frozen tissues were available. Sequencing analyses were performed by Sequenase PCR Product Sequencing Kit (Amersham, Little Chalfont, UK) according to the manufacturer's protocol. Nucleotide sequences of the primers were described previously . We sequenced the entire coding regions as well as their surrounding introns and 194-bp of the 5Ј-noncoding region and 36-bp of the 3Ј-noncoding region, but no mutations were observed. In 18 tumors from the paraffin blocks, the amounts of DNA were not large, and PCR amplifications of 120-bp or more were not easy. In these tumors, we could only analyze mutational hot spots in exons 7 and 8 (Kong et al. 1997) ; no mutations were observed.
Discussion Cairns et al. (1997) reported that 18% (11/60) of primary prostate tumors and 60% (12/20) of pelvic nodal metastases had allelic losses at the PTEN locus. Suzuki et al. (1998) also reported mutations of PTEN in 21% (4/19) of prostate cancer patients, all of them with metastases. Based on these observations, mutations of PTEN are probably a rather late event, as Steck et al. (1997) initially suggested. In this study, however, no genetic alterations were found in the PTEN gene in Japanese patients, although the incidence of allelic loss was almost equivalent to that in other reports of polymorphism in intron 4 of the PTEN gene as well as microsatellite markers D10S2491 and D10S2492 at the PTEN locus (Cairns et al. 1997 ). Examples of the LOH studies are shown in Figure 1A . Two (11.1%) of 18 informative cases showed LOHs at one or more loci; similar to those by Cairns et al. (1997) in primary prostate cancers (11/60, 18.3%). We further studied allelic loss by fluorescence in situ hybridization (FISH) in 12 tumors in which fresh materials were available. Two (16.7%) of 12 tumors showed allelic loss; none of the tumors exhibited homozygous deletion. A typical example is shown in Figure  1B . Two centromeric signals were clearly seen, but only one signal for the PTEN gene (bac554d23) was observed 
